Form 4: Anika Therapeutics Director Acquires Restricted Stock Units
SEC Form 4 Filing
Director Joseph H. Capper acquired 468 restricted stock units (RSUs) of Anika Therapeutics, Inc. on June 3, 2024, which will vest on the earlier of the next annual meeting or June 3, 2025.
Summary
- On June 3, 2024, Joseph H. Capper, a director of Anika Therapeutics, Inc., acquired 468 restricted stock units (RSUs).
- Each RSU represents the contingent right to receive one share of Anika Therapeutics' common stock.
- The RSUs will vest in full on the earlier of the next annual meeting of the company's stockholders or June 3, 2025.
- The transaction was reported on Form 4, filed with the SEC on June 5, 2024.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, indicating a standard transaction. It doesn't convey any particularly positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which is common for directors and officers of publicly traded companies.
Stakeholder Impact
- The acquisition of RSUs by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of transaction: Joseph H. Capper acquired 468 restricted stock units. |
| 06/03/2025 | RSUs vest in full on the earlier of the next annual meeting of the Company's stockholders or this date. |
| 06/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.